Malignant Melanoma: Who Shall Live and Who Shall Die?

Archives of Dermatology

Volumn 128, Issue 4, 1992, Pages 537-542

  Rivers, Jason K ^a   Ho, Vincent C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE; GROWTH FACTOR RECEPTOR; HLA ANTIGEN; IMMUNOLOGIC FACTOR;

AGE; ANTIBODY RESPONSE; CANCER; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME NOR; CYTOMETRY; EDITORIAL; HISTOPATHOLOGY; MELANOMA; MITOSIS RATE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SEX; SURVIVAL RATE; TUMOR GROWTH; TUMOR REGRESSION; UNITED STATES;

AGE FACTORS; HUMAN; MELANOMA; PROGNOSIS; SEX FACTORS; SKIN NEOPLASMS;

EID: 0026521747     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.1992.01680140117016     Document Type: Article

References (96)

1. 1. Balch CM, Soong S-J, Shaw HM, Milton GW. An analysis of prognostic factors in 4000 patients with cutaneous melanoma. In: Balch CM, Milton GW, eds. Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. Philadelphia, Pa: JB Lippincott; 1985: 321-352.
2. 2. Thorn M, Adami HO, Ringborg U, et al. Long-term survival in malignant melanoma with special reference to age and sex as prognostic factors. J Natl Cancer Inst. 1987; 79: 969-974.
3. 3. Cohen HJ, Cox E, Mantor K, et al. Malignant melanoma in the elderly. J Clin Oncol. 1987; 5: 100-106.
4. 4. Rivers JK, Kelly M, Kopf AW, Welkovich B, Bart RS. Age and malignant melanoma: comparison of variables in different age groups. J Am Acad Dermatol. 1989; 21: 717-722.
5. 5. Day CL, Mihm MC Jr, Sober AJ, et al. Prognostic factors for melanoma patients with lesions 0.76-1.69 mm in thickness: an appraisal of thin level IV lesions. Ann Surg. 1982; 195: 30-34.
6. 6. Day CL, Mihm MC Jr, Lew RA, et al. Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51-3.99 mm): a conceptual model for tumor growth and metastasis. Ann Surg. 1982; 195: 35-43.
7. 7. Day CL, Lew RA, Mihm MC Jr, et al. A multivariate analysis of prognostic factors for melanoma patients with lesions >3.65 thickness: the importance of revealing alternate Cox models. Ann Surg. 1982; 195: 44-49.
8. 8. Balch CM, Murad TM, Soong SJ, et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslows's staging method. Ann Surg. 1978; 188: 732-742.
9. 9. Karjalainen S, Hakulinen T. Survival and prognostic factors of patients with skin melanomas: a regression model analysis based upon nationwide cancer registry data. Cancer. 1988; 62: 2274-2280.
10. 10. Shaw HM, McGovern VJ, Milton GW, et al. Histologic features of tumors and the female superiority in survival from malignant melanoma. Cancer. 1980; 45: 1604-1608.
11. 11. Crowley NJ, Siegler HF. Late recurrence of malignant melanoma: analysis of 168 patients. Ann Surg. 1990: 212: 173-177.
12. 12. Thorn M, Adami HO, Ringborg V, et al. The association between anatomic site and survival in melanoma. Eur J Cancer Clin Oncol. 1989; 25: 483-491.
13. 13. Cascinelli N, Vaglini M, Bufalino, et al. BANS: a cutaneous region with no prognostic significance in patients with melanoma. Cancer. 1986; 57: 441-444.
14. 14. Rogers GS, Kopf AW, Rigel DS, et al. Influence of anatomic location on prognosis of malignant melanoma: attempt to verify the BANS model. J Am Acad Dermatol. 1986; 15: 231-237.
15. 15. Weinstock MA, Morris BT, Lederman JS, Bleicher P, Fitzpatrick TB, Sober AJ. Effects of BANS location of clinical stage I melanoma: new data and meta-analysis. Br J Dermatol. 1988; 119: 559-565.
16. 16. Manci EA, Balch CM, Murad TM, Soong SJ. Polypoid melanoma: a virulent variant of the nodular growth pattern. Am J Clin Pathol. 1981; 75: 810-815.
17. 17. McGovern VJ, Shaw HM, Milton GW. Prognosis in patients with malignant melanoma: influence of regression. Histopathology. 1983; 7: 673-680.
18. 18. Sober AJ, Day CL Jr, Kopf AW, et al. Detection of thin primary melanomas. CA. 1983; 3: 160-163.
19. 19. Reed KM, Bronstein BR, Mihm MC Jr, et al. Prognosis for polypoidal melanoma is determined by primary tumor thickness. Cancer. 1986; 57: 1201-1203.
20. 20. Kopf AW, Gross DF, Rogers GS, et al. Prognostic index for malignant melanoma. Cancer. 1987; 59: 1236-1241.
21. 21. Clark WH, From L, Bernadino EA, et al. The histogenesis and biologic behaviour of primary human malignant melanomas of the skin. Cancer Res. 1969; 29: 705-726.
22. 22. Balch CM, Soong SJ, Shaw HM. A comparison of worldwide melanoma data. In: Balch CM, Milton GW, Shaw HM, Soong SJ, eds. Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. Philadelphia, Pa: JB Lippincott; 1985: 507-518.
23. 23. Heenan PJ, Matz LR, Blackwell JB, et al. Inter-observer variation between pathologists in the classification of cutaneous malignant melanoma in Western Australia. Histopathology. 1984; 8: 717-729.
24. 24. Sober AJ, Day CL Jr, Fitzpatrick TB, et al. Early death from clinical stage I melanoma. J Invest Dermatol. 1983; 80(suppl): 50-52.
25. 25. Kelly JW, Sagebiel RW, Clyman S, Blois MS. Thin level IV melanoma: a subset in which level is the major prognostic indicator. Ann Surg. 1985; 202: 98-103.
26. 26. Slingluff CL, Vollmer RT, Reintgen DS, et al. Lethal ‘thin’ malignant melanoma: identifying patients at risk. Ann Surg. 1988; 208: 150-161.
27. 27. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970; 172: 902-908.
28. 28. Van der Esch EP, Cascinelli N, Preda F, et al. Stage I melanoma of the skin: evaluation of prognosis according to histologic characteristics. Cancer. 1983; 48: 1668-1673.
29. 29. Friedman RJ, Rigel DS, Kopf AW, et al. Volume of malignant melanoma is superior to thickness as a prognostic indicator. Dermatol Clin. 1991; 9: 643-648.
30. 30. McGovern VJ, Shaw HM, Milton GW, et al. Is malignant melanoma arising in a Hutchinson's melanotic freckle a separate disease entity? Histopathology. 1980; 4: 235-242.
31. 31. Koh HK, Michalik E, Sober AJ, et al. Lentigo maligna melanoma has no better prognosis that other types of melanoma. J Clin Oncol. 1984; 2: 994-1001.
32. 32. Clark WH Jr, Elder DE, Guerry D IV, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989; 81: 1893-1904.
33. 33. Larsen TE, Grude TH. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage, I: the relation of cell type, pigmentation, atypia and miotic count to histological type and prognosis. Acta Pathol Microbiol Scand. 1979; 86: 513-522.
34. 34. Schmoeckel C, Bockelbrink A, Bockelbrink H, et al. Low and high risk melanoma, I: evaluation of clinical and histologic prognosticators in 585 cases. Eur J Cancer Clin Oncol. 1983; 19: 227-235.
35. 35. McGovern VJ, Shaw HM, Milton GW, et al. Prognostic significance of the histopathologic features of malignant melanoma. Histopathology. 1979; 3: 385-393.
36. 36. Eldh J, Boeryd B, Peterson LE. Prognostic factors in cutaneous malignant melanoma in stage, I: a clinical, morphological and multivariate analysis. Scand J Plast Reconstr Surg. 1978; 12: 243-255.
37. 37. Day CL, Sober AJ, Kopf AW, et al. A prognostic model for clinical stage I melanoma of the lower extremity: location on foot as independent risk factor for recurrent disease. Surgery. 1981; 89: 599-603.
38. 38. Schmoeckel C, Braun-Falco O. Prognostic index in melanoma. Arch Dermatol. 1978; 114: 871-873.
39. 39. Shaw HM, McCarthy WH, McCarthy SW, Milton GW. Thin malignant melanomas and recurrence potential. Arch Surg. 1987; 122: 1147-1150.
40. 40. Kopf AW, Welkovich B, Frankel RE, et al. Thickness of malignant melanoma: global analysis of related factors. Dermatol Surg Oncol. 1987; 13: 345-420.
41. 41. Balch CM, Wilkerson JA, Murad TM, et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer. 1980; 45: 3012-3017.
42. 42. Day CL, Harrist TJ, Gorstein F, et al. Malignant melanoma: prognostic significance of ‘microscopic satellites’ in the reticular dermis and subcutaneous fat. Ann Surg. 1981; 194: 108-112.
43. 43. Harrist TJ, Rigel DS, Day CL, et al. Microscopic satellites are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer. 1984; 53: 2183-2187.
44. 44. Kelly JW, Sagebiel RW, Calderon W, et al. The frequency of local recurrence and micro satellites as a guide to re-excision margins for cutaneous malignant melanoma. Ann Surg. 1984; 200: 759-763.
45. 45. McGovern VJ, Shaw HM, Milton GW, et al. Lymphocytic infiltration and survival in malignant melanoma. In: Ackerman AB, ed. Pathology of Malignant Melanoma. New York, NY: Masson Publishing USA Inc; 1981: 341-344.
46. 46. Tefany FJ, Barnetson R, Halliday GM, McCarthy SW, McCarthy WH. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol. 1991; 97: 197-202.
47. 47. Gromet MA, Epstein WL, Blois MS. The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer. 1978; 42: 2282-2292.
48. 48. Czarnetzki BM, Denter M, Brocker EB, et al. Clinical features of superficial spreading melanomas with zones of regression. J Cancer Res Clin Oncol. 1984; 107: 225-228.
49. 49. Sondergaard K, Hou-Jensen K. Partial regression in thin cutaneous malignant melanomas clinical stage I. Virchows Arch A. 1985; 408: 241-247.
50. 50. Trau H, Rigel DS, Harris MN, et al. Metastases of thin melanomas. Cancer. 1983; 51: 553-556.
51. 51. Kelly JW, Sagebiel RW, Blois MS. Regression in malignant melanoma: a histological feature without independent prognostic significance. Cancer. 1985; 56: 2287-2291.
52. 52. Thompson JJ, Herlyn M, Elder DE, et al. Use of monoclonal antibodies in detection of melanoma-associated antigens in intact human tumors. Am J Pathol. 1982; 107: 357-361.
53. 53. Ruiter DJ, Bahn AK, Harrist TJ, et al. Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J Immunol. 1982; 129: 2808-2815.
54. 54. Natali PG, Cavaliere R, Bigotti A, et al. Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J Immunol. 1983; 130: 1462-1466.
55. 55. Ruiter DJ, Bergman W, Welvaart K, et al. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res. 1984; 44: 3930.
56. 56. Brocker EB, Suter L, Bruggen J, et al. Phenotypic dynamics of tumor progression in human malignant melanoma. Int J Cancer. 1985; 36: 29-35.
57. 57. van Diunen SG, Ruiter DJ, Hageman P, et al. Immunohistochemical and histochemical tools in the diagnosis of amelanotic melanoma. Cancer. 1984; 53: 1566-1573.
58. 58. Johnson JP, Lehmann JM, Stade BG, Rothbacher U, Sers C, Reithmuller G. Functional aspects of three molecules associated with metastasis development in human malignant melanoma. Invasion Metastasis. 1989; 9: 338-350.
59. 59. Holzmann B, Johnson JP, Kaudewitz P, Riethmuller G. In situ analysis of antigens on malignant and benign cells of the melanocytic lineage: differential expression of 2 surface molecules, gp75 and p89. J Exp Med. 1985; 161: 366-377.
60. 60. Holzmann B, Brocker EB, Lehmann JM, et al. Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer. 1987; 39: 466-471.
61. 61. Holzmann B, Lehmann JM, Ziegler-Heitbrock HW, Funke I, Riethmuller G, Johnson JP. Glycoprotein P3.58, associated with tumor progression in malignant melanoma, is a novel leukocyte activation antigen. Int J Cancer. 1988; 41: 542-547.
62. 62. Johnson JP, Stade BG, Holzmann B, Schwable W, Riethmuller G. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci U S A. 1989; 86: 641-644.
63. 63. Natali PG, Nicotra MR, Cavaliere R, et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res. 1990; 50: 1271-1278.
64. 64. Lehmann JM, Riethmuller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A. 1989; 86: 9891-9895.
65. 65. Ravindranath MH, Tsuchida T, Morton DL, Irie RF. Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer. 1991; 67: 3029-3035.
66. 66. Herlyn M, Clark WH, Rodeck U, et al. Biology of disease: biology of tumor progression in human melanocytes. Lab Invest. 1987; 56: 461-474.
67. 67. Hoon DSB, Irie RF, Cochran AJ. Gangliosides from human melanoma immunomodulate response of T-cells to IL-2. Cell Immunol. 1988; 111: 1-10.
68. 68. Rodeck U, Melber K, Kath R, et al. Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J Invest Dermatol. 1991; 97: 20-26.
69. 69. Vlock DR, Kirkwood JM. Serial studies of autologous antibody reactivity to melanoma: relationship to circulating immune complexes and clinical course. J Clin Invest. 1985; 876: 879-884.
70. 70. Vlock DR, DerSimonian R, Kirkwood JM. Prognostic role of antibody reactivity to melanoma. J Clin Invest. 1986; 77: 1116-1121.
71. 71. Rosen RD, Crane MM, Morgan AC, et al. Circulating immune complexes and tumor cell cytotoxins as prognostic indicators in malignant melanoma: a prospective study of 53 patients. Cancer. 1983; 43: 422-429.
72. 72. Gupta RK, Morton DL. Clinical significance and nature of circulating immune complexes in melanoma patients. Contemp Top Immunobiol. 1985; 15: 1-53.
73. 73. Jones PC, Sze LL, Liu PY, et al. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst. 1981; 66: 249-254.
74. 74. Werkmeister JA, Edwards W, McCarthy W, et al. Prognostic significance of expression of antigens on melanoma cells. Cancer Immunol Immunother. 1980; 9: 233-240.
75. 75. Heenan PJ, Jarvis LR, de Klerk NH, Armstrong BK. Nuclear indices and survival in cutaneous melanoma. Am J Dermatopathol. 1989; 11: 308-312.
76. 76. Kheir SM, Bines SD, Von Roenn JH, et al. Prognostic significance of DNA aneuploidy in stage I cutaneous melanoma. Ann Surg. 1988; 207: 455-461.
77. 77. Silver HKB, Karim KA, Le Riche J, et al. Nuclear DNA, serum sialic acid and measured depth in malignant melanoma for predicting disease recurrence and survival. Int J Cancer. 1989; 44: 31-34.
78. 78. Von Roenn JH, Kheir SM, Wolter JM, Coon JS. Significance of DNA abnormalities in primary malignant melanoma and nevi: a retrospective flow cytometric study. Cancer Res. 1986; 46: 3192-3195.
79. 79. Bartkowiak D, Schumann J, Otto F, Lippold A, Drepper H. DNA flow cytometry in the prognosis of primary malignant melanoma. Oncology. 1991; 48: 39-43.
80. 80. Lindholm C, Hofer P-A, Jonsson H, Tribukait B. Flow DNA-cytometric findings of paraffin-embedded primary cutaneous melanomas related to prognosis. Virchows Arch B. 1989; 58: 147-151.
81. 81. Gattuso P, Reddy V, Solans E, et al. Is DNA ploidy of prognostic significance in stage I cutaneous melanoma? Surgery. 1990; 108: 702-709.
82. 82. Rivers JK, McCarthy SW, Shaw HM, et al. Patients with thick melanomas surviving at least 10 years: histological, cytometric and HLA analyses. Histopathology. 1991; 18: 339-346.
83. 83. Lindholm C, Hofer PA, Jonsson H. Single cell DNA cytophotometry in clinical stage I malignant melanoma. Acta Oncol. 1990; 29: 147-150.
84. 84. Howat AJ, Wright AL, Cotton DWK, Reeve S, Bleehen SS. AgNORs in benign, dysplastic, and malignant melanocytic skin lesions. Am J Dermatopathol. 1990; 12: 156-161.
85. 85. Crocker J, Skilbeck N. Nucleolar organiser region associated proteins in cutaneous melanotic lesions: a quantitative study. J Clin Pathol. 1987; 40: 885-889.
86. 86. Gonzalez-Campora R, Armas-Padron J, Rios-Martin JJ, Lopez-Garrido J, Gomez-Pascual A, Galera-Davidson H. Nucleolar organizer regions in pigmented skin lesions: value in the differential diagnosis of spitz nevi. Anal Quant Cytol Histol. 1991; 13: 16-22.
87. 87. Fallowfield ME, Cook MG. The value of nucleolar organizer region staining in the differential diagnosis of borderline melanocytic lesions. Histopathology. 1989; 14: 299-304.
88. 88. Leong AS-Y, Gilham P. Silver staining of nucleolar organizer regions in malignant melanoma and melanotic nevi. Hum Pathol. 1989; 20: 257-262.
89. 89. Friedman RJ, Grin CM, Heilman E, et al. Distinguishing benign and malignant melanocytic lesions with the AgNOR method. Dermatol Clin. 1991; 9: 689-693.
90. 90. Mackie RM, White SI, Seywright MM, Young H. An assessment of the value of AgNOR staining in the identification of dysplastic and other borderline melanocytic naevi. Br J Dermatol. 1989; 120: 511-516.
91. 91. Gambini C, Casazza C, Borgiani L, et al. Counting on nucleolar organizer region—associated proteins is a prognostic clue of malignant melanoma. Arch Dermatol. 1992; 128: 487-490.
92. 92. Howat AJ, Giri DD, Wright AL, Underwood JCE. Silver-stained nucleoli and nucleolar organizer region counts are of no prognostic value in thick cutaneous malignant melanoma. J Pathol. 1988; 156: 227-232.
93. 93. Smith PJ, Skilbeck N, Harrison A, Crocker J. The effect of a series of fixatives on the AgNOR technique. J Pathol. 1988; 155: 109-112.
94. 94. Griffiths AP, Butler CW, Roberts P, Dixon MF, Quirke P. Silver-stained structures (AgNORs), their dependence on tissue fixation and absence of prognostic relevance in rectal adenocarcinoma. J Pathol. 1989; 159: 121-127.
95. 95. Orrell JM, Evans AT, Grant A. A critical evaluation of AgNOR counting in benign naevi and malignant melanoma. J Pathol. 1991; 163: 239-244.
96. 96. White R, Rigel DS, Friedman RJ. Computer applications in the diagnosis and prognosis of malignant melanoma. Dermatol Clin. 1991; 9: 695-702.